ReviewThe Journal of clinical endocrinology and metabolism2023
New-Onset Diabetes After COVID-19.
Review in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.Expert reviews in molecular medicine · 2026Pooled it
- Association of race, ethnicity, and pediatric long COVID and MIS-C: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Prevalence of new-onset diabetes following COVID-19 infection: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.Clinical and molecular hepatology · 2026Article
- Estimating the Clinical, Quality-of-Life and Economic Impact of Optimized Management of Type 2 Diabetes Patients in Spain.Journal of clinical medicine · 2026Article
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- Long-term health effects of COVID-19 among patients in Croatian primary care settings.Frontiers in medicine · 2026Article
- Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients.Therapeutic advances in endocrinology and metabolism · 2026Article
- Bidirectional associations between chronic diseases and Long COVID: a population-based cohort and interrupted time-series analysis.Frontiers in public health · 2026Article
- Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.International urology and nephrology · 2025Review
- PROTOCOL: New-Onset Diabetes Mellitus Post COVID-19 Infection: A Protocol for Systematic Review and Meta-Analysis: A Systematic Review.Campbell systematic reviews · 2025Article
- Predictive diagnostic models for newly diagnosed diabetes mellitus in moderate to severe COVID-19: the role of TyG Index, BMI, and inflammatory markers.BMC endocrine disorders · 2025Article
- Epidemiological trend in diabetic kidney disease (DKD) burden in China from 1990 to 2021, and projections for 2041: an analysis of the global burden of disease study 2021.BMC public health · 2025Article
- Article
- Severe and Intractable Hypokalemia in a Patient With New-onset Type 1 Diabetes and COVID-19 Infection.JCEM case reports · 2025Article
- Aspirin reduces the risk of type 2 diabetes associated with COVID-19.npj metabolic health and disease · 2025Article
- Post-COVID Metabolic Fallout: A Growing Threat of New-Onset and Exacerbated Diabetes.Biomedicines · 2025Review
- Risk of New-Onset Diabetes Before and During the COVID-19 Pandemic: A Real-World Cohort Study.Journal of general internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is evidence suggesting that infection with SARS-CoV-2 can lead to several long-term sequelae including diabetes. This mini-review examines the rapidly evolving and conflicting literature on new-onset diabetes after COVID-19, which we term NODAC. We searched PubMed, MEDLINE, and medRxiv from inception until December 1, 2022, using Medical Subject Headings (MeSH) terms and free text words including "COVID-19," "SARS-CoV-2," "diabetes," "hyperglycemia," "insulin resistance," and "pancreatic β-cell." We also supplemented searches by examining reference lists from retrieved articles. Current evidence suggests that COVID-19 increases the risk of developing diabetes, but the attributable risk is uncertain because of limitations of study designs and the evolving nature of the pandemic, including new variants, widespread population exposure to the virus, diagnostic options for COVID-19, and vaccination status. The etiology of diabetes after COVID-19 is likely multifactorial and includes factors associated with host characteristics (eg, age), social determinants of health (eg, deprivation index), and pandemic-related effects both at the personal (eg, psychosocial stress) and the societal-community level (eg, containment measures). COVID-19 may have direct and indirect effects on pancreatic β-cell function and insulin sensitivity related to the acute infection and its treatment (eg, glucocorticoids); autoimmunity; persistent viral residency in multiple organs including adipose tissue; endothelial dysfunction; and hyperinflammatory state. While our understanding of NODAC continues to evolve, consideration should be given for diabetes to be classified as a post-COVID syndrome, in addition to traditional classifications of diabetes (eg, type 1 or type 2), so that the pathophysiology, natural history, and optimal management can be studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.